Keywords: Basilea, Johnson & Johnson, Ceftobiprole, Arbitration award, Astellas, Isavuconazole
Basilea awarded $130 million in breach of contract arbitration with Johnson & Johnson; updates on isavuconazole program
Article | 30 November 2010
Switzerland-based Basilea Pharmaceutica (SIX: BSLN) announced yesterday that a Dutch arbitration tribunal has found US drug major Johnson & Johnson ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
